Developing in-007 as a widely deployable inhaled treatment against pathogens utilizing human ACE2 for viral attachment and entry
Active Definitive Contract Awarded Last action
- Contract number
- HT942524C0076
- Awardee
-
Inhalon Biopharma, Inc. UEI HFQSJ2GMNRU6
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $2,234,650
Award facts
- Opportunity
-
- HT942523SJWMR Solicitation number
- Contract value 100% obligated
- $2,234,650.00 Current and potential, with all options
- Completion date 94% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 47 offers Basic Research
- Pricing
- Fixed Price Level of Effort
- Place of performance
- Morrisville, NC, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Original award | $2,234,650 |
About this award
The Defense Health Agency awarded a $2.23M fixed-price level of effort contract to Inhalon Biopharma, Inc. on September 23, 2024, for the development of IN-007, an inhaled therapeutic treatment targeting pathogens that utilize human ACE2 receptors for viral attachment and entry. The contract, which carries no set-aside designation, is scheduled for completion by December 22, 2026, and will be performed at Inhalon's facilities in Morrisville, North Carolina. The revised statement of work includes a principal investigator change and encompasses comprehensive research activities including cell line development, good manufacturing practice (GMP) manufacturing, animal studies, and regulatory submissions necessary to advance the treatment toward clinical application.
Inhalon Biopharma is a clinical-stage biopharmaceutical company specializing in inhaled monoclonal antibody therapies for respiratory infections, leveraging a proprietary platform of muco-trapping antibody treatments administered via handheld nebulizers. This Defense Health Agency contract aligns with the company's existing portfolio of federally funded research, including approximately $3M in grants from the National Institute of Allergy and Infectious Diseases supporting the development of inhaled antibody therapies targeting respiratory syncytial virus, influenza A, human metapneumovirus, and COVID-19. The IN-007 development effort represents a significant investment in creating a broadly deployable respiratory therapeutic capability for the military health system.
Quick answers
Who was awarded contract HT942524C0076?
HT942524C0076 was awarded to Inhalon Biopharma, Inc. by Defense Health Agency (Department of Defense) on September 23, 2024.
How much is contract HT942524C0076 worth?
The government has obligated $2,234,650 on HT942524C0076.
Was contract HT942524C0076 competed?
The extent of competition for HT942524C0076 was full and open competition. The government received 47 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award